{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bites-human-animal/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"696d5b30-ff2f-5b72-875c-03cf5db390c0","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field 68a4976e-a488-4616-a8a2-a877009b6af6 --><h2>Metronidazole</h2><!-- end field 68a4976e-a488-4616-a8a2-a877009b6af6 -->","summary":"","htmlStringContent":"<!-- begin item 3e0c6c07-63ce-4613-89e5-a877009b6866 --><!-- end item 3e0c6c07-63ce-4613-89e5-a877009b6866 -->","topic":{"id":"66885481-1c78-50d7-bd40-cee6daf3a22b","topicId":"1f9ba5f4-d4ca-402b-857f-1ef0227e6eaa","topicName":"Bites - human and animal","slug":"bites-human-animal","lastRevised":"Last revised in October 2020","chapters":[{"id":"4d7c4615-e565-58f7-ab3f-9af67d5fa066","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d9aea4af-b77b-548e-a62d-b1b69d689e70","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b16f539f-9832-520a-b08e-b9870416e2ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"814b9650-9309-581c-ad8b-77bd0f59d573","slug":"changes","fullItemName":"Changes"},{"id":"451e8923-57cf-55b9-88b6-7767cf1870b3","slug":"update","fullItemName":"Update"}]},{"id":"4f4d63cd-fedc-53a6-9963-001d4f253f2c","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8bb57dc0-b6ce-5ebb-a31d-25b2d527ed6c","slug":"goals","fullItemName":"Goals"},{"id":"51f172a3-e955-5bda-98c3-61a0bd719f16","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"150a707d-3a0a-5115-b633-9ab844daab23","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"77f07ad2-c9ad-5bc2-9b81-5c305f9e8ca3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"51c4f343-6ac9-549d-a068-43084108f8c5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"909ff9e5-d816-5a1a-a545-0b5d010352f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"601e2fbe-0e18-597e-9476-633c9f4ef7b3","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5c3cdd6-9531-5a6c-b1bc-a6e8d12b2307","slug":"definition","fullItemName":"Definition"},{"id":"2158dea0-437f-5805-9e65-e1c277e52475","slug":"characteristics-of-different-types-of-bites","fullItemName":"Characteristics of different types of bites"},{"id":"dcc5a332-7954-5ea2-88e1-7093a2c27960","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d2e33eaa-035d-54f9-b1e6-ee9d3c605297","slug":"complications","fullItemName":"Complications"},{"id":"f9c4fd96-ca8a-53ba-bb96-fe24ea11c8be","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"27cd943b-33a7-5304-8c4f-0f2da1c77fb9","fullItemName":"Management","slug":"management","subChapters":[{"id":"4a38ec65-3aac-5dff-b0e6-ce328b564e2d","slug":"managing-a-human-bite","fullItemName":"Scenario: Managing a human bite"},{"id":"3998b5bd-33dc-52ed-848d-b1c3b6d01573","slug":"managing-a-cat-or-dog-bite","fullItemName":"Scenario: Managing a cat or dog bite"}]},{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a0c8184c-9c4d-5943-9d34-6471f2fe8744","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"0e041b11-cf29-519b-99be-1751ece6b17e","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"7398d7dd-8a7d-5695-b963-bba32a0445a8","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"696d5b30-ff2f-5b72-875c-03cf5db390c0","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"6410092b-90ae-58a9-8065-103199eca1cb","slug":"paracetamol-ibuprofen","fullItemName":"Paracetamol and ibuprofen"}]},{"id":"703fd48e-b059-5fac-8aef-986c90ceca15","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"869edd83-cb34-55d6-9d47-6931a23adf4e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"8e9f1883-896e-54dd-8156-ae8a2aa744d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3edab9d3-1d3a-5e9d-b8df-83d2ffc14bf0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8e969da1-bdae-5ba7-9471-72cff35d2dac","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"e8d0ba91-234c-5494-a990-bbe559b68c05","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0e2e4ab4-ad2f-5ad9-a9c6-3d59693be83c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"bdc0f3ee-0644-5a81-b04b-3f1ae3e4310b","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"cc488aaa-0221-5616-92c9-e9b9a28c206a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5bb6d240-a1ae-5879-9255-1a52adf695c4","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field f98cf4a8-6d1c-4a77-971d-a877009e0079 --><h3>What dosage of metronidazole should I prescribe?</h3><!-- end field f98cf4a8-6d1c-4a77-971d-a877009e0079 -->","summary":"","htmlStringContent":"<!-- begin item 10f7c60d-f3ce-4413-9785-a877009dfd5c --><!-- begin field fda44ec9-c8db-4db4-b237-a877009e0079 --><ul><li>For treatment of an infected bite wound, the dosage of oral metronidazole is:<ul><li>Adult: 400 mg 3 times a day for 5 days.</li><li>Child 12–17 years: 400 mg 3 times a day for 5 days.</li></ul></li><li>For prophylaxis of a bite the dosages are as described above but prescribed for 3 days. </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">NICE, 2020</a>]</p><!-- end field fda44ec9-c8db-4db4-b237-a877009e0079 --><!-- end item 10f7c60d-f3ce-4413-9785-a877009dfd5c -->","subChapters":[]},{"id":"4c61ba2f-0e1b-576a-8923-cda4469c8cfb","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b5217552-2ad6-4ca2-9915-a877009e6e3f --><h3>What are the contraindications and cautions when prescribing metronidazole?</h3><!-- end field b5217552-2ad6-4ca2-9915-a877009e6e3f -->","summary":"","htmlStringContent":"<!-- begin item f589be04-f330-48f4-888c-a877009e6b14 --><!-- begin field ed3a92f2-a35d-482b-b2e4-a877009e6e3f --><ul><li><strong>Do not prescribe metronidazole in people with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li></ul></li><li><strong>Prescribe metronidazole with caution in people with:</strong><ul><li>Cockayne syndrome — cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use (oral and suppositories).</li><li>Only prescribe after careful benefit-risk assessment and only if no alternative treatment is available. Liver function tests must be performed just prior to the start of therapy, throughout and at the end of treatment until liver function is within normal ranges, or until the baseline values are reached.</li><li>Active or chronic severe peripheral and central nervous system disease, as there is a risk of neurological aggravation.</li><li>Severe liver disease or hepatic encephalopathy — prescribe one-third of the daily dosage once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>] </p><!-- end field ed3a92f2-a35d-482b-b2e4-a877009e6e3f --><!-- end item f589be04-f330-48f4-888c-a877009e6b14 -->","subChapters":[]},{"id":"b28f745c-1537-5373-872c-ba15fbb9e399","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 8beeb776-30be-471a-b668-a877009e98df --><h3>What are the adverse effects of metronidazole?</h3><!-- end field 8beeb776-30be-471a-b668-a877009e98df -->","summary":"","htmlStringContent":"<!-- begin item f02cdb85-71eb-4b6e-b74c-a877009e95b9 --><!-- begin field 6b47266f-63bf-44f2-9f29-a877009e98df --><ul><li><strong>Blood disorders </strong>— agranulocytosis, neutropenia, thrombocytopenia, pancytopenia (very rare).</li><li><strong>Eye </strong>— transient diplopia, myopia (very rare).</li><li><strong>Gastrointestinal </strong>— nausea, vomiting, anorexia, epigastric pain, taste disturbances, furred tongue, oral mucositis (unknown frequency).</li><li><strong>Nervous system</strong> — drowsiness, dizziness, convulsions, headaches, encephalopathy (very rare)</li><li><strong>Psychiatric</strong> — confusion, hallucinations (very rare).</li><li><strong>Skin </strong>— rash, pruritus, flushing, erythema multiforme, Stevens–Johnson syndrome or toxic epidermal necrolysis, fixed drug eruption (very rare).</li><li><strong>Other rare, or very rare adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Darkening of urine.</li><li>Hearing impairment, tinnitus.</li><li>Liver enzyme increases, jaundice, pancreatitis.</li><li>Myalgia, arthralgia.</li><li>Severe bullous skin reactions such as Stevens-Johnson–syndrome, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis (AGEP) have been reported. If symptoms/signs are present, treatment must be immediately discontinued.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>]</p><!-- end field 6b47266f-63bf-44f2-9f29-a877009e98df --><!-- end item f02cdb85-71eb-4b6e-b74c-a877009e95b9 -->","subChapters":[]},{"id":"e7aad600-8646-5995-93eb-cbeb77efce51","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0a06c9f4-12c9-430a-bb49-a877009ebf59 --><h3>What drug interactions are associated with metronidazole?</h3><!-- end field 0a06c9f4-12c9-430a-bb49-a877009ebf59 -->","summary":"","htmlStringContent":"<!-- begin item 689650bc-c28a-46cb-94ef-a877009ebbbd --><!-- begin field d747abf5-2ca4-4f94-acee-a877009ebf59 --><ul><li><strong>Alcohol </strong>— some people taking metronidazole experience a disulfiram-like reaction with alcohol.<ul><li>Warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst on metronidazole and for at least 48 hours afterwards. </li></ul></li><li><strong>Busulfan </strong>— plasma levels of busulfan may be increased leading to toxicity. Avoid high doses of busulfan. If conventional doses of busulfan are given, monitor blood count weekly.</li><li><strong>Ciclosporin</strong> — levels of ciclosporin may be increased. If co-administration of metronidazole and ciclosporin is necessary, serum ciclosporin levels and serum creatinine should be closely monitored.</li><li><strong>5-fluorouracil</strong> — metronidazole reduces the clearance of 5-fluorouracil, increasing the risk of toxicity.</li><li><strong>Lithium </strong>— seek specialist advice regarding the use of metronidazole with lithium, as metronidazole increases the risk of lithium toxicity. Lithium dose reduction may be required due to the risk of renal damage with concurrent use. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored if metronidazole and lithium are used simultaneously.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of metronidazole.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Phenobarbital </strong>— the metabolism of metronidazole is increased significantly. The dose of metronidazole may need to be increased.</li><li><strong>Warfarin</strong> — the anticoagulant effects of warfarin may be increased by metronidazole. <ul><li>Monitor the international normalized ratio (INR) and adjust the warfarin dose accordingly. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">ABPI, 2017d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bites-human-animal/references/\">FSRH, 2017</a>]</p><!-- end field d747abf5-2ca4-4f94-acee-a877009ebf59 --><!-- end item 689650bc-c28a-46cb-94ef-a877009ebbbd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}